Full text
Earnings transcript
Read the complete earnings call transcript.
AMRX
Amneal Pharmaceuticals, Inc.
$19.93
-0.28
(-1.39%)
| Exchange: | NASDAQ |
| Market Cap: | 6.942B |
| Shares Outstanding: | 313.367M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | Drug Manufacturers – Specialty & GenericView industry performance | |||||
| CEO: | Chirag K. Patel | |||||
| Full Time Employees: | 8700 | |||||
| Address: |
| |||||
| Website: | https://www.amneal.com |
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson’s disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Click to read more…
Revenue Segmentation
Revenue by type
Revenue by region
Industry Peers
| TICKER | COMPANY | MKT CAP | P/E | FWD P/E | ROIC |
|---|---|---|---|---|---|
| AMRX | Amneal Pharmaceuticals, Inc. | 6.9B | 43.2 | 19.2 | 13.4% |
 LNTH | Lantheus Holdings, Inc. | 6.6B | 23.9 | 18.7 | 11.0% |
 ALKS | Alkermes plc | 7.7B | 113 | — | 2.1% |
 INDV | Indivior Pharmaceuticals Inc | 4.5B | 9.7 | 9.0 | 95.4% |
 BHC | Bausch Health Companies Inc. | 3.1B | — | 1.8 | 14.4% |
 RGC | Regencell Bioscience Holdings Limited | 2.8B | — | — | -85.9% |
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 2,393,607 | 2,793,957 | 3,018,760 |
| Gross Profit | 863,869 | 1,020,438 | 1,136,092 |
| EBITDA | 500,782 | 439,773 | 603,872 |
| Operating Income | 204,374 | 249,326 | 423,090 |
| Net Income | -83,993 | -116,886 | 72,057 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 3,472,569 | 3,501,445 | 3,678,280 |
| Total Liabilities | 3,452,558 | 3,545,983 | 2,790,684 |
| Total Stockholders Equity | 19,781 | -109,267 | 887,596 |
| Total Debt | 2,750,523 | 2,593,139 | 123,931 |
| Cash and Cash Equivalents | 91,542 | 110,552 | 282,029 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 345,577 | 295,099 | 339,992 |
| Capital Expenditure | -69,189 | -51,924 | -70,063 |
| Free Cash Flow | 276,388 | 243,175 | 269,929 |
| Net Income | -48,722 | -73,876 | 72,057 |
| Net Change in Cash | 63,880 | 19,313 | 194,519 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2029 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 4,482,738.750 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 4,583,070.469 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 4,531,500 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 1,251,399.586 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 1,276,431.174 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 1,263,564.649 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 579,672.989 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 596,595.329 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 587,897.051 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 788,780.955 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 806,435.285 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 797,360.966 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 1.810 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 1.840 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 1.780 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 2 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 1 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates AMRX intrinsic value between $25.10 – $26.07 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about AMRX valuation
Is Amneal Pharmaceuticals, Inc. (AMRX) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Amneal Pharmaceuticals, Inc. (AMRX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is AMRX a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether AMRX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is AMRX’s P/E ratio?
You can see AMRX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for AMRX?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is AMRX a good long-term investment?
Whether AMRX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
AMRX
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-1.39
Trading Metrics:
| Open: | 20.55 | Previous Close: | 20.21 | |
| Day Low: | 19.02 | Day High: | 20.55 | |
| Year Low: | 11.14 | Year High: | 21.68 | |
| Price Avg 50: | 19.22 | Price Avg 200: | 15.81 | |
| Volume: | 1.453M | Average Volume: | 2.666M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
